Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate UpdateGlobeNewsWire • 03/09/26
Corbus Pharmaceuticals to Present at the 36th Annual Oppenheimer Healthcare Life Sciences ConferenceGlobeNewsWire • 02/12/26
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/15/26
Corbus Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/05/26
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Phase 1a Single-Ascending and Multiple-Ascending Dose Data TranscriptSeeking Alpha • 12/11/25
Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight LossGlobeNewsWire • 12/11/25
Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025GlobeNewsWire • 12/10/25
Corbus Pharmaceuticals: Data Update And Fundraising Efforts Do Not Diminish The ThesisSeeking Alpha • 11/05/25
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses CRB-701 Data and Insights in Head and Neck Cancer Panel TranscriptSeeking Alpha • 10/20/25
Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25GlobeNewsWire • 10/18/25
FDA Grants Fast Track Designation to Corbus Pharmaceuticals' Nectin-4 Targeting ADC CRB-701 in Head and Neck Squamous Cell CarcinomaGlobeNewsWire • 09/16/25
Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with PembrolizumabGlobeNewsWire • 06/25/25
Corbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity SymposiumGlobeNewsWire • 06/24/25
Corbus Pharmaceuticals: Is Its Pipeline Really Worthless After Novo's Negative Data?Seeking Alpha • 06/17/25
3 Stocks Targeting Weight Loss Market With Cannabinoid-Based TherapiesZacks Investment Research • 05/23/25
Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare ConferenceGlobeNewsWire • 05/22/25
Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board ChairGlobeNewsWire • 05/19/25
Wall Street Analysts See a 764.18% Upside in Corbus Pharmaceuticals (CRBP): Can the Stock Really Move This High?Zacks Investment Research • 04/18/25
Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of ObesityGlobeNewsWire • 03/28/25